Amgen Inc. ($AMGN) announced Monday that it will offer its cholesterol-lowering drug Repatha at a nearly 60% discount to U.S. patients, aligning with President Donald Trump’s directive for pharmaceutical companies to reduce domestic drug prices.
- Repatha will now be available for $239 per month through Amgen’s new online platform, AmgenNow.
- The company plans to integrate AmgenNow with TrumpRx, a federal website facilitating direct-to-consumer drug sales.
- The discounted U.S. price marks Repatha’s lowest cost among G-7 nations, following Trump’s “most-favored nation” pricing initiative.
- Repatha’s list price has dropped from $14,100 annually in 2015 to $6,876, and now to $2,868 per year under the new offer.
- Amgen’s move follows Trump’s letters to 17 major drugmakers demanding immediate price cuts, global price parity, and direct-to-consumer sales channels.
- Pfizer recently secured tariff relief after complying with the administration’s drug pricing mandates, while other negotiations remain ongoing.
Relevant Companies
- Amgen ($AMGN) — Implementing direct-to-consumer sales with lower U.S. pricing for Repatha.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
